Hundreds of nominations were submitted this year to The Healthcare Technology Report and winners were selected based on leaders’ contributions to the advancement of medicine and the biotechnology industry.
BERKELEY, Calif., Feb. 16, 2022 -- ActymThanos
Hundreds of nominations were submitted this year to The Healthcare Technology Report and winners were selected based on leaders’ contributions to the advancement of medicine and the biotechnology industry.
“I am honored and humbled to be named one of Healthcare Technology Report’s Top 25 CEOs in Biotech,” said Dr. Thanos. “I am tremendously grateful for the incredibly talented colleagues that I work alongside with at Actym. Your hard work and commitment inspires me every day to help build next generation therapies that bring benefit to patients stricken with cancer.”
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector.
To learn more about the award and the other individuals included in the list, please click here.
About Actym
ActymBerkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncologyimmunotherapeuticSTACTTyphimurium-AttenuatedpreclinicalSTACTSTACTimmuno-modulatorytoxicitiesSTACTActym$34 million in a Series A financing, co-led by Boehringer-IngelheimIlluminaJLO
Media Contact:
Valerie Enes
Seismic Media Relations
valerie@teamseismic.com
Corporate Contact:
Sheriese Rush, MBA
Head of Operations, Actym Therapeutics, Inc.
srush@actymthera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actym-therapeutics-ceo-dr-christopher-thanos-named-one-of-the-top-25-biotech-ceos-of-2022-301484171.html
SOURCE Actym Therapeutics Inc.
